These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 31715289)

  • 21. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
    Wu J; Lin Z
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted/emerging therapies for metastatic non-small cell lung cancer.
    Horn L
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):676-8. PubMed ID: 25995428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized targeted therapy in advanced non-small cell lung cancer.
    Ma PC
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
    Meador CB; Hata AN
    Pharmacol Ther; 2020 Jun; 210():107522. PubMed ID: 32151666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the Mechanisms of Resistance in
    Del Re M; Crucitta S; Gianfilippo G; Passaro A; Petrini I; Restante G; Michelucci A; Fogli S; de Marinis F; Porta C; Chella A; Danesi R
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
    Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for NSCLC with driver mutations.
    Minuti G; D'Incecco A; Cappuzzo F
    Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successes and limitations of targeted cancer therapy in lung cancer.
    Suda K; Mitsudomi T
    Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
    Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
    Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
    McCoach CE; Bivona TG; Blakely CM; Doebele RC
    Clin Lung Cancer; 2016 Sep; 17(5):466-469. PubMed ID: 27378174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of targeted agents for non-small cell lung cancer.
    Vestergaard HH; Christensen MR; Lassen UN
    Acta Oncol; 2018 Feb; 57(2):176-186. PubMed ID: 29172833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
    Brosseau S; Oulkhouir Y; Naltet C; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S27-33. PubMed ID: 26118873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
    Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
    Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
    Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.